ArticleBMC immunology2025
Mp1p antigen as a sensitive diagnostic marker for early detection and treatment monitoring of Talaromyces Marneffei infection.
Article in BMC immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diagnostic performance of a biotin-labeled 4D1 sandwich ELISA for serum antigen detection in talaromycosis.PLoS neglected tropical diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundTalaromyces marneffei (TM) is a life-threatening opportunistic fungal pathogen, particularly in individuals with advanced HIV/AIDS. Early and accurate diagnosis remains challenging due to the limited sensitivity and specificity of conventional microbiological and antigen-based tests. Mp1p, a secreted TM-specific virulence protein, has emerged as a promising target for serological diagnosis. This study aimed to evaluate the diagnostic performance of Mp1p antigen and antibody detection using ELISA in sera from HIV infected patients with confirmed TM infection.
methodsA total of 36 confirmed TM-infected patients (including fungemia and non-fungemia cases), 269 HIV/AIDS patients with fever but without TM infection, 37 cryptococcosis patients, and 218 healthy blood donors were enrolled from two tertiary hospitals in China (2020–2024). Recombinant Mp1p protein was expressed and purified to develop Mp1p antigen and antibody ELISAs. Diagnostic sensitivity and specificity were calculated. Serial samples before and after antifungal therapy were evaluated to determine the utility of Mp1p antigen and antibody levels in treatment monitoring and recurrence detection. Results were compared with established diagnostic tools, including galactomannan (GM) and cryptococcal antigen (CrAg) assays.
resultsMp1p antigen ELISA demonstrated high sensitivity (94.4%) and specificity (98.5%) for TM infection. In contrast, Mp1p antibody ELISA had lower sensitivity (25.0%) but equally high specificity (98.5%). Mp1p antigen levels significantly declined after amphotericin B (AMB) treatment (mean OD₄₅₀: 1.654 ± 0.723 pre-treatment vs. 0.355 ± 0.488 post-treatment; p < 0.0001), supporting its role in treatment monitoring. Antigen levels were significantly higher in fungemic versus non-fungemic patients (p = 0.001). Among initially antibody-negative patients, 56.3% seroconverted within one year, suggesting delayed antibody response. Mp1p antigen levels rebounded in one relapsed patients before clinical deterioration, while antibody levels did not change, highlighting the antigen's potential for early relapse detection.
conclusionsMp1p antigen ELISA is a highly sensitive and specific tool for early diagnosis and therapeutic monitoring ofTM infection in HIV-infected patients. Its performance exceeds current serological assays and is especially valuable in identifying fungemia and potential relapse. In contrast, Mp1p antibody detection is limited in early-stage diagnosis due to delayed seroconversion. Incorporating Mp1p antigen testing into clinical workflows may significantly improve patient outcomes through earlier intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.